• Uber Technologies has built a global ride-sharing empire thanks to a successful model of sustaining peer-to-peer transportation business operations
• Criminal incidents that have played on the vulnerabilities of ride-share drivers and passengers have led to a series of recent security enhancements available to Uber users through the company’s mobile app
• The new RideCheck feature uses the phone’s geolocation capabilities in combination with the platform’s AI-driven protocols to monitor potential concerns and respond by contacting both the driver and the passenger
• The RideCheck feature was tested in U.S. cities including Los Angeles and Dallas and is expected to roll out soon to the international market, where Uber delivers services in more than 60 countries

As media reports have highlighted some dangers experienced by both drivers and passengers using rideshare services during recent years, multinational peer transportation company Uber Technologies Inc. (NYSE: UBER) has developed a series of enhanced security features designed to help protect the people using its amenities.

After a University of South Carolina college student was kidnapped and murdered earlier this year when she got into a car she mistakenly believed to be her Uber ride, the well-known rideshare company launched its Campus Safety Initiative to help students learn how to avoid fake rideshare drivers (http://ibn.fm/UpxyM). The program features specified places for picking up rides on college campuses and a ‘Check Your Ride’ phone app notification element that reminds riders to verify the details of the vehicle they are anticipating.

In September, Uber announced a new safety feature for its app that offers greater assistance to passengers and drivers using the ride-hailing service. The new RideCheck feature uses the location sensors in smartphones to detect the movements of Uber’s vehicles (http://ibn.fm/Hr46h). The system uses artificial intelligence enhancements to determine if a car is doing anything unexpected along its route, such as stopping at a premature location or veering off on an untrusted course.

In the event of a triggering event, the system will send an alert to both the driver and the passenger to ask if there’s a problem. The individuals can then tap on the alert to indicate if assistance is needed or to state that, “I’m fine.”

Uber’s safety team may be alerted to follow up with a phone call as well, depending on the circumstances.

“Helping keep millions of riders and drivers around the world safe is a huge responsibility with unique challenges,” Head of Safety Products Sachin Kansal stated in a blog post about the feature (http://ibn.fm/qdq0a). “While I’m proud of the progress we’ve made, when it comes to safety, we know our work is never done.”

Other safety elements introduced by the company include the addition of an in-app panic button for contacting 911, a listing of trusted people the company can contact on behalf of the Uber user and the centralization of safety features within the app.

The RideCheck feature was tested in major U.S. cities like Los Angeles and Dallas, and it will soon be available in other countries as well. In April, Uber’s officers reported that the company was operating in 63 countries on six continents, providing more than 14 million trips per day in more than 700 cities (http://ibn.fm/vV0VM). The report stated that Uber’s near-term expansion plans were focused on increasing ridesharing services in Argentina, Germany, Italy, Japan, South Korea and Spain.

“Every day, our technology puts millions of people together in cars in cities around the world,” CEO Dara Khosrowshahi stated last year in a blog post (http://ibn.fm/Z1Z3T). “Helping keep people safe is a huge responsibility, and one we do not take lightly.”

For more information, visit the company’s website at www.Uber.com

• Earth Science Tech offers biotech expertise in the largest sector of the legal cannabis market
• The CBD market is projected to see 700 percent growth through 2019
• ETST’s portfolio is designed to further establish its position in the burgeoning sector

Earth Science Tech Inc. (OTCQB: ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid, nutraceutical, pharmaceutical and medical device research and development. With biotech being the largest sector of the legal cannabis market (http://ibn.fm/Jx6JA), ETST appears ideally poised to be a key player in the burgeoning space.

Brightfield Group, a leading market and consumer intelligence firm for the legal cannabinoids and cannabis industries, recently reported that the U.S. CBD market was projected to see an unprecedented 700 percent growth through 2019 (http://ibn.fm/YHh0w). With hemp-derived CBD increasingly being used in health, wellness and anti-pharma products, the market is actually estimated to reach $23.7 billion by 2023.

Biotech researchers are committed to uncovering innovative new ways that CBD can be used for medicinal and other purposes. ETST recognizes the opportunity and is leveraging its background and expertise in both biotech and cannabis to firmly establish its position in the space. As part of that strategy, the company is widening its reach through strategic partnerships designed to develop new and novel cannabinoid-based pharmaceutical and nutraceutical products.

Included in Earth Science Tech’s portfolio are three wholly owned subsidiaries focused on expanding the company’s work in the pharmaceutical and medical device sectors. These subsidiaries include Cannabis Therapeutics Inc., KannaBidioiD (“KBD”) and Earth Science Pharma.

Cannabis Therapeutics Inc. is leading out in the development of new, cutting-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.

KannaBidioiD provides a variety of products designed for the recreational cannabis arena. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and e-liquid products.

Earth Science Pharma Inc. is committed to the development of low-cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.

Earth Science Tech’s current and pipeline offerings provide a variety of products and unique formulations. As legalization of medical marijuana spreads, investment opportunities in the cannabis biotech sector continue to grow.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• VPRB’s electronic cigarette patent is one of the first originally filed; it dates back to 2009
• The popularity of auto-draw technology in vaping devices creates an ‘opportune’ time for the company to consider licensing intellectual property
• The e-cigarette and vaping industries are predicted to grow at a global CAGR of 24.9 percent from 2019 to 2025

As demand for e-cigarettes and vaping technologies grows into a multibillion-dollar industry, key players in the space are seeking to protect their proprietary technologies against patent theft. One such innovator is VPR Brands LP (OTCQB: VPRB), a multi-vertical tiered technology holding company in the cannabis space, including vaping. The company is seeking to protect its e-cigarette utility patent, one of the first originally filed electronic cigarette patents dating back to 2009, against infringement. At the same time, VPR Brands is exploring alternative routes of licensing or even selling its patented auto-draw technology, a valuable asset (http://ibn.fm/zKakZ).

This conflict over proprietary rights has a notable history in the industry. In 2014, The Economist reported the story of Fontem Ventures, a Netherlands-based subsidiary of Britain’s Imperial Tobacco that sued 11 American e-cigarette makers (http://ibn.fm/h9jGh). A sea of litigation and acquisitions later, Imperial remains a key player in the e-cigarette and vaping market and is the owner of several broad patents, the analysis found. At that time, the American vaping market was just beginning its growth and was valued at a mere $1.5 billion.

Years later, with the market having quadrupled in size, the stakes are markedly higher. The value of trademarks in this space has grown, and companies must be increasingly vigilant to safeguard their patent rights. Grand View Research found that North America is the largest global regional market in the e-cigarette and vaping space at an estimated $4.6 billion in 2018. The industry is predicted to grow at a global CAGR of 24.9 percent from 2019 to 2025. Globally, the e-cigarette and vaping market was seen in 2018 as reaching $10.3 billion and expanding at a CAGR of 24.9 percent through 2025 (http://ibn.fm/Llbta). The impressive rate at which the industry is growing has created an entrepreneurial attraction to newcomers in the space, causing a critical need for more established companies like VPR Brands to protect their trade secrets.

“The surge of the vaping category for nicotine, cannabis and CBD in the last few years has reached billions of dollars in sales,” VPR Brands CEO Kevin Frija stated in a news release. “This has resulted in opportunities for our patented auto-draw technology, which we believe is now preferred by many users of pod systems and ‘cigalikes’.” Frija added that these conditions have created an “opportune time to consider licensing, enforcement, or potentially a sale of [the company’s] intellectual property to one of the larger players in the space who may then be in a better position to snub out many of the counterfeit or black market vapes.”

VPRB is also seeking to develop a monetization infringement enforcement plan for its American utility patent, the company said. It is exploring its legal options and strategies related to prosecuting offenders and is gauging available remedies. Additionally, VPRB is investigating buttonless vape devices that initiate vaporization from the user’s airflow inhalation, which are suspected to infringe on VPRB’s utility patent.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at  http://ibn.fm/VPRB

• POAI’s artificial intelligence (AI)-driven tumor profiling platform brings precision medicine tools to clinicians and researchers to improve cancer outcomes
• The company holds a critical strategic advantage over mammoth competitors, attracting investor attention
• POAI is committed to providing sophisticated tools to help select current therapies more precisely and develop new targeted therapies

Predictive Oncology Inc. (NASDAQ: POAI) is working with the pharmaceutical and biotech industries to offer an AI-driven tumor profiling platform that clinicians and researchers can use to improve outcomes for cancer patients of today and tomorrow. POAI has built a distinctly valuable asset in its existing base of drug-response outcome evidence; this data has the potential to revolutionize the way cancer is treated (http://ibn.fm/M1mcR).

Though seeming like David in the face of Goliath-sized competition, POAI holds a critical strategic advantage over such mammoth companies as Foundation Medicine and Tempus; while these competitors must wait at least five years to find out if the patient survived treatment before they can show value from their investments in gathering data, POAI’s dataset already contains large amounts of data going back more than 10 years, allowing it to build predictive models much more quickly and robustly. By simply analyzing the tumor it has already banked, Predictive Oncology can combine this with the drug response data it already has, delivering valuable, actionable insights to clinicians and researchers in months rather than years.

POAI’s technology combines its database of evidence documenting actual drug responses of cancer patients’ tumors with artificial intelligence (AI) to create an invaluable predictive tool for clinicians and researchers. Predictive Oncology’s data offers a valuable customizable assessment method that can be used by oncologists to determine the best drug for fighting a specific patient’s cancer. This disruptive technology is the first of its kind and is also meeting a critical need in the pharmaceutical, diagnostic and biotech industries to speed up the search for new precision therapies by providing tools to better predict how new drugs work on different cancers (http://ibn.fm/0YnNI).

POAI’s wholly owned subsidiaries – Helomics and TumorGenesis – are working together to bring these important precision medicine tools to physicians. “The TumorGenesis platform and its methodology for tagging a tumor’s diverse cancer cell population is highly complementary to our Helomics discovery service business, which utilizes AI-driven tumor genetic and drug response profiling,” POAI CEO Dr. Carl Schwartz stated in a news release (http://ibn.fm/f5o4f). “Our vision is to tag every patient’s complex tumor cell populations first with biomarkers, creating a unique ‘fingerprint’ of that tumor to deliver a personalized medicine approach to cancer treatment.”

Massachusetts-based genetic profiling company Foundation Medicine, which was taken over by Swiss company Roche in 2018, is continuing to grow its own dataset on the treatment of patients with cancer. Similarly, Chicago-based Tempus has worked to sequence patient tumors and is mining medical records to look for outcomes.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Geyser Brands’ first revenues of $79,434, generated during Q1 2019, represent a gross profit margin of 81 percent
• The company is nearing final TSX Venture Exchange conditional approval of its transaction to acquire Solace Management Group Inc.
• Geyser Brands subsidiary Apothecary Botanicals has received a standard processing license from Health Canada, which will allow the company to extend its CBD products to the regulated Canadian consumer medical market

Geyser Brands Inc. (TSX.V: GYSR), a global science-led consumer health care company that builds and markets some of the world’s most loved cannabis products and brands, continues to achieve its stated strategic goals. Financial statements for the three months ended June 30, 2019, show Geyser Brands reporting revenues of $79,434, representing an 81 percent gross profit margin.

“We have begun to operationalize our manufacturing and processing capabilities, generating our first revenues during Q1. We are continuing to explore new brand opportunities and develop our manufacturing capacity to position the company for rapid expansion as our remaining Health Canada licenses get awarded,” CEO Andreas Thatcher stated in a news release (http://ibn.fm/XdjCI). “I am excited about the many opportunities that have been presented to us for producing and distributing hemp-based products on a global basis. We look forward to delivering additional, high-margin revenue streams once our R&D and sales licensing are in place.”

As a licensed producer in Canada under the Cannabis Act, Geyser operates a production and processing facility in Port Coquitlam, British Columbia, developing unique products for healthy lifestyle brands (http://ibn.fm/HzqC0). The company’s wholly owned subsidiary, Apothecary Botanicals, recently received a standard processing license from Health Canada, which Thatcher characterized as “a huge milestone” for the company.

“The license allows us to add value to existing consumer health care brands by providing them the platform to add CBD,” Thatcher stated in a news release (http://ibn.fm/9WBe0). “It also reflects our business model to focus our licensed producer on delivering scale through manufacturing and distribution for brand companies.”

An earlier announced acquisition of Solace Management Group Inc. is also moving ahead on target. Geyser Brands is working to provide the TSX Venture Exchange with the necessary documents and anticipates receipt of final approval shortly, the company stated. Solace, which carries a dynamic portfolio of both pet and consumer health care goods, is situated in a new, 7,500 square foot, GMP-compliant manufacturing facility, which is expected to increase production capacity of its hemp-related human and pet products by up to tenfold (http://ibn.fm/cwiuL).

Geyser Brands creates hemp and cannabis products and brands for the nutraceutical, cosmetics, food and beverage and pet sectors. Its proprietary nanotechnology formulation, termed ‘NanoFusion Technology’, solves the insolubility problem of most hemp and cannabis products with an advanced delivery system that quickly and efficiently transports therapeutic agents directly to the bloodstream for maximum absorbency (http://ibn.fm/xPmRk).

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

• Strategic acquisitions are an important part of Neutra Corp.’s expansion strategy aimed at securing a better position on the CBD retail market
• The company has completed its acquisition of VIVIS, an emerging retail brand of hemp-based health and nutritional products
• Superior quality and third-party certification set VIVIS apart from other market competitors and allow for effortless differentiation

On September 10, 2019, Neutra Corp. (OTCQB: NTRR) completed a previously announced acquisition of VIVIS Corp., an emerging retail brand of hemp-based wellness and health products, founded to offer clients high quality, potent hemp-extracted solutions. This area of specialization makes VIVIS a great match to the Neutra philosophy, as the company said in a news release (http://ibn.fm/2rqIC).

“VIVIS gives us an up-and-coming retail brand that’s gaining a solid market standing for quality, potency and customer satisfaction. With the respected VIVIS name on Neutra’s CBD products, we expect to gain a strong foothold in the hemp-based CBD market,” Neutra President Sydney Jim said in a news release.

One of the biggest distinctions between VIVIS products and other solutions on the market is that the company has third-party certification. This means that an independent lab inspects the quality of the VIVIS products to make sure they’re contaminant-free and consistent in terms of quality from batch to batch.

The CBD product market is expanding rapidly, with a growing number of companies entering the field as CBD continues to become increasingly popular. As a result, consumers are only likely to become more discerning when looking for CBD products. Differentiation and proof of quality have already started playing a role in the selection of one brand or another. Legislative changes and a higher level of awareness regarding the benefits of CBD have both contributed to the market explosion.

By 2024, the CBD market in the U.S. alone is anticipated to reach $20 billion (http://ibn.fm/PCZx7). Market analysis companies are estimating that the compound annual growth rate will reach 49 percent across all distribution channels.

This market shift is also characterized by a rapid change in consumers’ mindset. CBD consumers are aged 40 on average, and they have a higher level of education. They typically support market legalization; nearly 66 percent of the people who use hemp-derived CBD products support full federal cannabis legalization, because 90 percent of these people believe in its medicinal benefits.

Such changing attitudes are likely to fuel even more profound market changes in the years to come. The companies that are already well-positioned to enter the CBD retail market will reap the benefits in the near future.

Neutra Corp. is an early stage research and development company that relies on cutting edge technologies for the development of nutraceuticals, food and drug and environmental purification solutions.

Currently, Neutra is focusing on positioning itself as a vertically integrated company that is able to cultivate, manufacture and distribute its own hemp-based CBD products. To establish its market position, the company is seeking new and existing opportunities that can accelerate its mission and help Neutra innovations reach a wider demographic.

For more information, visit the company’s website at www.NeutraInc.com

NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR

• Predictive Oncology is working to develop highly customizable assessment methods to individualize treatment options for cancer, improving outcomes
• POAI’s innovative technology is pioneering in the field of individualizing treatment for ovarian cancer
• Predictive Oncology offers potential for significant ROI as it focuses on improving outcomes for cancer patients of today and tomorrow

Predictive Oncology Inc. (NASDAQ: POAI) is harnessing its unique, proprietary database of cancer cases using the proven power of artificial intelligence (AI) to revolutionize treatment outcomes for cancer patients. The company works alongside pharmaceutical, diagnostic and biotechnology industry players to develop highly customizable assessment methods that can be applied to both individualize current therapies and develop the next generation of precision therapies, leading to better outcomes for patients. The company recently announced a corporate name change from Precision Therapeutics to Predictive Oncology Inc., which reflects its mission and strategic emphasis.

Predictive Oncology seeks to revolutionize the way cancer is treated for both the patients of today and those of tomorrow. The company is well positioned to do exactly that as a result of two key assets: its ability to grow patients’ own tumors in the laboratory and test the tumors’ responses to chemotherapy, together with its existing database of outcome data cataloguing more than 150,000 tumors and their specific responses to those chemotherapies.

POAI’s innovative technology enables the company to be a pioneer in the field of precision oncology, putting the patient at the heart of both selecting treatments and the development of new treatments. While the use of AI in precision medicine has been improving oncologists’ ability to diagnose cancer for several years (http://ibn.fm/ZsmGN), the ability to accurately prescribe the correct treatment for all but a few patients has been absent. Applying a guess-and-check methodology, doctors have limited ability to prescribe the most effective drug to treat patients. This approach relegates patients with cancer to the role of guinea pigs, trying new drugs and waiting to see the extent to which they are effective.

Oncologists are realizing that knowledge of genomics, or simply knowing the genetic markers of a tumor, is not enough to beat cancer. The ability to better predict which drugs affect certain types of cancer vastly improves the efficacy of oncologists’ recommendations. This is the void POAI’s technology can fill.

By utilizing its rich base of data, which includes not only diagnostic/genomic information but also unique response data which indicates how certain cancer types have responded to certain drugs, POAI’s predictive models guide doctors to more effectively individualize therapy. Without having to wait to discover if the patient responds to a drug, POAI’s technology is giving cancer patients an earlier indication of efficacy, and hence more favorable odds for recovery, without squandering their time, a commodity that many patients don’t have.

In addition, the company has been working with two major partners to validate its predictive models: Interpace Diagnostics Group Inc. and UPMC Magee-Women’s Hospital. While primarily utilizing its technology to create a predictive model for ovarian cancer, POAI’s goal is to grow, applying its methodologies and leveraging its huge database to impact cancers such as breast, colon and others.

POAI came about as an acquisition between Skyline Medical and Helomics. Helomics applies AI to its rich data gathered from patient tumors to customize cancer therapies for individual patients and drive the development of new targeted therapies in collaboration with pharmaceutical firms.

In addition, POAI’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory. This process essentially “fools” cancer cells into thinking they are still growing inside a patient. TumorGenesis’ approach is expected to provide a much more relevant model of patients’ tumors that may be used for testing of drugs, personalized therapy or the development of new drugs.

Based in Eagan, Minnesota, POAI operates via three business units: Helomics, TumorGenesis and Skyline Medical. Predictive Oncology continues to take advantage of the synergies of its subsidiaries to bring precision medicine to the treatment of cancer. The company is at the vanguard of innovation in using AI in precision cancer treatment. For investors, Predictive Oncology offers the potential for significant ROI as it focuses on improving patient outcomes.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• Spectrum Global Solutions Inc. is a solution and service provider for carriers, aggregators, utilities and enterprise clients
• The company provides both wireless and wireline services and solutions, with offerings ranging from small and local to extensive and large-scale
• SGSI is well-positioned to capitalize on the 5G rollout planned for 2019 and beyond

Spectrum Global Solutions Inc. (OTCQB: SGSI) provides excellent solutions for next-generation wireless networks through its professional services and installation capabilities for service providers and corporate enterprise markets. Part of the mission of Spectrum Global Solutions is to be the premier world-class industry leader providing the best services possible at the highest levels of quality, reliability and safety. Reliability is critical for network performance, and high-quality installations help ensure that the standard is met.

Clients thus depend on Spectrum Global Solutions to receive solutions that are of a high standard such that their infrastructure and network systems are not compromised in any way. Safety and security are also crucial in the corporate world today. This is an aspect of network technologies which Spectrum Global understands and strives to consistently maintain.

Spectrum Global Solutions provides an array of broadband solutions, as well as wireless and wireline network infrastructure and services, to both the carrier and enterprise markets in Canada, the United States, Guam, Puerto Rico and the islands of the Caribbean. Spectrum Global Solutions is a unique industry leader as a single-source provider in the telecommunications arena, providing those solutions that are both most appropriate and optimal for its clients. In the future, telecommunications services are expected to increase, and the need for support is expected to record a similar trajectory with more installations and services being in demand.

Broadband network solutions that are provided include the installation of fiber networks and the associated infrastructure required for these networks to function optimally. Spectrum Global Solutions’ professional engineers and technicians are responsible for both the deployment and maintenance of these broadband fiber networks and infrastructure, as well as wireless Distributed Antenna System (DAS)/small cells. The services also vary in scope from a single activity to multi-region, large-scale turnkey solutions.

These services are provided directly to carriers, aggregators, utilities and enterprise companies. In addition, there are also professional services teams that Spectrum Global Solutions offers to major carrier clients, original equipment manufacturer (OEM) clients and project management organizations (PMO).

Spectrum Global owns and operates several different subsidiaries, enabling it to provide services covering wireless, wireline and fiber network infrastructure and client=based professional services. These subsidiaries include such companies as AW Solutions LLC, ADEX Corporation LLC, TNS Inc. and Tropical Communications Inc. Spectrum Global has shown continued growth through subsidiaries ADEX and AW Solutions Inc., reaching $19.7 million in revenue in the first half of 2019 largely due to its expansion of these subsidiaries.

ADEX Corporation (http://ibn.fm/z7uy3) is headquarters in the state of Georgia and has an exceptional track record in employing top technical professionals who can assist with the provision of network infrastructure, both within the United States and elsewhere around the world. They also offer scalable services, from basic to very advanced, when it comes to installation of networks. This scalability is an advantage, as it allows clients to expand and build more complex infrastructure networks at a future date if the need arises. Spectrum Global has secured a three-year nationwide contract renewal with a tier-1 U.S. telecommunications company through its ADEX subsidiary.

Although smaller in scope than ADEX Corporation, Tropical Communications Inc. (http://ibn.fm/qGHlL) provides and installs communications infrastructure in the Southeast for carriers and enterprise clientele. The firm is headquartered in Miami, Florida.

AW Solutions Inc. and AW Solutions Puerto Rico LLC (http://ibn.fm/P9fRN) both provide full turnkey services and solutions for both broadband and wireless network systems. AW Solutions has the benefit of being licensed in every state in the continental United States and the islands of Hawaii, as well as U.S.-held territories such as Puerto Rico, the U.S. Virgin Islands and Guam. The company is also licensed in several provinces in Canada, including Alberta, British Columbia, New Brunswick, Ontario and Quebec.

TNS Inc. provides full turnkey telecommunications service solutions to domestic and international clients. The in-demand service offerings of TNS Inc. have it deploying and implementing projects throughout the entirety of the U.S., Canada and Mexico. TNS is headquartered in Illinois.

The rollout of rapid 5G networks in 2019 is expected to further boost the delivery of services to clients around the nation and around the world. 5G networks will have increased compatibility and higher network data transmission speeds, greatly improving on wireless network service delivery and solutions. Greater data speeds and better wireless systems are expected to be a big boost for services provided to the telecommunications industry.

Services and solutions offered by Spectrum Global will only increase in need in the future as such technologies as 5G become more commonplace and as the need for safe, reliable networks and infrastructure increases. Spectrum Global Solutions is well-positioned in the market to take advantage of the expected increase in business that will come when 5G rollout occurs sometime in 2019.

For more information, visit the company’s website at www.SpectrumGlobalSolutions.com

NOTE TO INVESTORS: The latest news and updates relating to SGSI are available in the company’s newsroom at http://ibn.fm/SGSI

• Geyser Brands recently announced the TSX Venture Exchange’s conditional approval of its acquisition of Solace Management Group
• One of Solace Management Group’s most noteworthy assets is Apawthecary Pets – a line of hemp-based pet treats, salves and oral drops available for purchase throughout Canada
• Geyser also presented its financial results for the eight months ended in March 31, 2019, as well as providing several strategic milestones that will be determining for the growth and stability of the company in the future

Global science-led consumer health care company Geyser Brands Inc. (TSX.V: GYSR) recently announced that it was ready to move forward with a major strategic acquisition following its conditional approval by the TSX Venture Exchange. In a press release issued on August 6, 2019, the company said that it expects to complete the acquisition of Solace Management Group Inc. by the end of the month, subject to the terms of the definitive agreement (http://ibn.fm/kCtHa).

Once the transaction is completed, Geyser Brands will have access to Solace’s brands and assets, which include the popular Apawthecary Pets line of products. Apawthecary Pets is a leading, natural and hemp-based range of pet treats with formulations for human-grade pet treats, salves and oral drops. The company’s pet products are available throughout stores and vet clinics in Canada.

Solace’s product portfolio features 23 products and 57 SKUs for both pet products and consumer health care goods. All of the products are made with organic, cold-pressed and unrefined hemp seed oil extract.

Geyser’s important announcements did not end there. Previously, the company presented its financial results for the eight months ended March 31, 2019 (http://ibn.fm/Dc9Pn). “We are pleased with our progress in the first eight months since completing the RTO. Our subsidiary, 0957203 B.C. Ltd. dba Apothecary Botanicals, through its strong management, has been successful in bringing its facility to GMP-compliant standards for manufacturing and processing and in obtaining Health Canada licensing for Cultivation and Standard Processing,” Geyser CEO Andreas Thatcher said in a news release.

The financial report features a couple of important highlights that stand as evidence of Geyser’s growth. As of March 2019, the company’s total assets reached $4,890,422, in comparison to $4,504,411 as of July 31, 2018. Total shareholders’ equity reached $3,843,153 (from $3,405,399 in July 2018).

During the reporting period, Geyser completed equity financing that resulted in total proceeds from private placements of $2,015,140, as well as $76,500 from exercise of warrants. Geyser intends to use the proceeds from the financing for the completion of capital projects, potential acquisitions, research and development, commercialization of manufacturing capabilities and working capital purposes.

Finally, Geyser also announced its filing of amended and restated unaudited condensed consolidated interim financial statements for the three- and six-month periods ended January 31, 2019.

The restated interim financials and the corresponding management discussion can both be accessed via the company’s profile on SEDAR. The restated January interim financials replace and supersede previously filed January interim financials.

Geyser Brands works on the development of hemp-based consumer products in the nutraceutical, cosmetics, food and beverage and pet sectors. The company has an international presence, and it owns a Health Canada-approved licensed producer in Port Coquitlam, British Columbia, that has cultivation and processing licenses and is in anticipation of receiving research and development and sales licenses.

For more information, visit the company’s website at www.GeyserBrands.com

NOTE TO INVESTORS: The latest news and updates relating to GYSR are available in the company’s newsroom at http://ibn.fm/GYSR

• ChineseInvestors.com is a leading financial information website for Chinese-speaking investors
• The company reported a 175 percent year-over-year increase in revenue for FY2019
• CIIX’s CBD Biotech Inc. division recently launched six new skincare products

ChineseInvestors.com Inc. (OTCQB: CIIX) is a foremost financial information website for Chinese-speaking investors in the United States and China. In addition, via its CBD division (CBD Biotech Inc.), the company was focusing on cannabidiol (CBD)-based nutrition and health products. However, the company’s current plan is to return focus to its original mission of providing financial information and services to the larger Chinese community in the United States and elsewhere. Established in 1999, ChineseInvestors.com is based in San Gabriel, California (http://ibn.fm/R3ymn), and it has been operating its premier financial information website for 18 years.

CIIX offers an array of investor education products and services on its main website, www.ChineseInvestors.com. The company provides real-time market commentary, analysis and education-related services in Chinese language character sets, including both traditional and simplified. The company also offers its proprietary ChineseInvestors Method, an innovative integration of a disciplined investing process, web-based tools, personalized instructions and support. Therefore, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

Moreover, CIIX provides consultative services to smaller private businesses that are considering going public. The company also provides advertising and public relations-related support services. Additionally, CIIX raises awareness through investor conferences and road shows.

Recently, CIIX provided an update on its financial results for the fiscal year ended May 31, 2019, as well as an outlook for fiscal year 2020 (http://ibn.fm/AO8WR). The company reported a 175 percent year-over-year increase in revenue for FY2019, with $4,189,935 in sales revenue from industrial hemp and CBD liquor products in FY2019. This number is up from $378,984 in FY2018.

Furthermore, CIIX reported $1,336,402 in investor relations revenues in FY2019, up from $968,282 in FY2018. The company’s subscription revenue in FY2019 was $865,457, up from $779,964 in FY2018. The majority (95 percent) of CIIX’s subscriber base (free and paid members) is located in the United States and Canada. The company’s services are generally delivered to U.S. public and private businesses and also U.S. residents and citizens (http://ibn.fm/WW00f).

“While we have been strategically focusing on industrial hemp and CBD sales, we are pleased with the progress we have seen in our legacy businesses, financial news, education subscriptions, and investor relations, where we are re-focused on organic growth,” CIIX CEO Warren Wang stated in a news release. “We expect to see the full result of these efforts in FY2020.”

Wang also noted that CIIX hopes for a Nasdaq IPO of CBD Biotech late in FY2019 or early next year. CIIX would then concentrate on identifying an acquisition target for further growth (http://ibn.fm/WPOqV).

In addition, CIIX recently announced that CBD Biotech launched six new products in combination with its long-term strategic plans to expand its hemp/CBD skincare offerings. CBD Biotech’s new products include CBD Oligopeptides Repair Eye Cream, CBD Nerve Acylamide Eye Essence, CBD Hemp Eye Mask, CBD Gold Nicotinamide Essence, CBD Handmade Horse Oil Soap and CBD Clear Bright. These products are designed to complement the company’s present skincare lines and increase brand loyalty and awareness.

CIIX is re-focusing on its legacy business of providing first-rate financial information and services to the larger Chinese community. Of note for investors is that the company anticipates doubling its sales over the next 12 months. CIIX continues to execute on its strategy of solidifying its position as the leading financial information website for Chinese-speaking investors in the U.S. and China.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX